Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 11/20 | 0.57 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092481 | 0.91 | TNFRSF1A (0.58) | TNFRSF1AERN1HDAC6AVPR1AACLY | |
| SCHEMBL6094833 | 0.82 | TNFRSF1A (0.46) | TNFRSF1AERN1HDAC6AVPR1AACLY | |
| SCHEMBL5960621 | 0.79 | TNFRSF1A (0.62) | TNFRSF1AERN1 | |
| SCHEMBL6091643 | 0.78 | TNFRSF1A (0.59) | TNFRSF1AERN1AVPR1A | |
| SCHEMBL6091620 | 0.76 | TNFRSF1A (0.52) | TNFRSF1AHDAC6AVPR1AACLYCNR2 | |
| SCHEMBL5960639 | 0.74 | ERN1 (0.63) | TNFRSF1AERN1AVPR1AACLY | |
| SCHEMBL5960657 | 0.73 | TNFRSF1A (0.83) | TNFRSF1A | |
| SCHEMBL5960658 | 0.73 | TNFRSF1A (0.83) | TNFRSF1A | |
| SCHEMBL5571802 | 0.73 | TNFRSF1A (1.00) | TNFRSF1A | |
| SCHEMBL4727944 | 0.73 | TNFRSF1A (0.81) | TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | claimed |
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | TNFRSF1A 4880/4885ERN1 2367/4885HDAC6 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.